Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of alternating weekly temozolomide with delayed radiotherapy in newly diagnosed glioblastoma
ChiCTR1900027057Phase 2Recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: overall survival. Started Jan 2019; status: recruiting.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR1900027057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027057.